MetaCap

Allarity Therapeutics (ALLR) vs Citius Pharmaceuticals (CTXR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Allarity Therapeutics (ALLR) has outperformed Citius Pharmaceuticals (CTXR) over the past year, losing 25.9% versus a loss of 55.4%. Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $12.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALLR-25.94%CTXR-55.39%
+74%-0%-74%
Nov 21, 20251 yearNov 20, 2026
ALLR-100.00%CTXR-98.79%
+18%-44%-106%
Dec 20, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALLR versus CTXR key metrics
MetricALLRCTXR
Share price$0.785$0.5085
Market cap$12.56M$13.96M
1-day change-9.25%+2.27%
YTD return-27.31%-34.56%
1-year return-25.94%-55.39%
5-year return—-98.79%
EPS (TTM)$-0.79$-1.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$320.00K—
Net income (latest FY)$-11.23M$-39.74M
Operating margin-3939.06%—
Net margin-3509.69%—
52-week high$1.84$1.54
52-week low$0.769$0.37
Distance from 52-week high-57.34%-66.98%
Analyst consensusnonenone
Avg. price target upside+1301.27%+686.63%
Average volume131.74K275.44K
Shares outstanding16.00M27.45M
Employees723
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALLR has outperformed CTXR by 29.5 percentage points over the past year.

About Allarity Therapeutics

ALLR stock →

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Citius Pharmaceuticals

CTXR stock →

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

ALLR vs CTXR FAQ

Which is bigger, Allarity Therapeutics or Citius Pharmaceuticals?

Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $12.56M for Allarity Therapeutics (ALLR).

Which stock has performed better over the past year, ALLR or CTXR?

ALLR returned -25.94% over the past 12 months, compared with -55.39% for CTXR (price return, excluding dividends). Past performance does not predict future results.

Are Allarity Therapeutics and Citius Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons